AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00287638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive pressure device with a time clock
Study NCT01707069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals.
Study NCT02166840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stent (7-10Fr)
Study NCT02166840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self Expanding Metal Stent
Study NCT05782920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
Study NCT05782920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non cross-linked hyaluronic acid
Description: HA filling is a known modality for rejuvenation
Study NCT05782920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: topical HA gel
Description: the standard treatment of vaginal atrophy and dryness
Study NCT03238235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: suspension of Givinostat (10 mg/mL)
Study NCT00287638 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no CPAP
Study NCT04424485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy (TT)
Description: Standard TT procedure for thyroid carcinoma, for both groups
Study NCT04424485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy (TT)
Description: Standard TT procedure for thyroid carcinoma, for both groups
Study NCT04424485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central lymph node dissection (CLND)
Description: Standard CLND for thyroid carcinoma, for both groups
Study NCT04424485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central lymph node dissection (CLND)
Description: Standard CLND for thyroid carcinoma, for both groups
Study NCT04424485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) bopsy
Description: Intrathyroidal injection of ICG for SL biopsy, for only experimental group
Study NCT04424485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification of parathyroid glands (PGs)
Description: Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
Study NCT04785183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin drops
Description: Melatonin oral administration
Study NCT04785183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral 5% glucose
Study NCT01125202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCT-based behavioral intervention
Description: Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
Study NCT01125202 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
Study NCT02775617 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ivermectin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
Study NCT02775617 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
Study NCT02775617 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Permethrin
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
Study NCT00875641 — intervention group
Intervention type: OTHER
Intervention: Health Insurance Database
Description: Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
Study NCT04198961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opioid prescribing
Description: Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
Study NCT01857453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatine
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
Study NCT01857453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
Study NCT01857453 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
Study NCT02235610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLP Group
Description: EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
Study NCT02335268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Plate / romiplostim
Description: medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
Study NCT01441778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSS nasal irrigation salt
Description: nasal irrigation twice daily for 4 weeks period
Study NCT03238235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: suspension manufactured to mimic Givinostat
Study NCT00863928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belladonna 16.2 mg and opium 60 mg suppository
Description: belladonna 16.2 mg and opium 60 mg suppository
Study NCT06400238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06400238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06400238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT01441778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHS nasal irrigation salt
Description: nasal irrigation twice daily for 4 weeks period
Study NCT01505075 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation
Description: 40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
Study NCT04827225 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Questionnaires (EPDS, HADS, PPQ, MIBS, etc.) will have to be completed by the parents at different stages of their child's development (38 weeks of amenorrhea, 3 months and 24 months).
Study NCT04390464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
Study NCT04390464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
Study NCT04390464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Regular standard of care for COVID-19 patients
Study NCT06400238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03900884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
Study NCT03900884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
Study NCT03900884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
Study NCT01055782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoguide
Description: Use of endoguide to facilitate completion of endoscopy
Study NCT04612595 — intervention group
Intervention type: OTHER
Intervention: serum urea nitrogen to creatinine ratio
Description: According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO
Study NCT01096602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC AML Vaccine
Description: Group 1: 2-3 doses of the vaccine at 4 week intervals
Study NCT03311945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (1200 mg QD)
Study NCT03311945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine (300 mg QD)
Study NCT04666753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: ImmunoFormulation
Description: The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
Study NCT02902133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetazolamide
Description: Acetazolamide 500 mg by mouth twice per day for 5 days
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00769587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT01941069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friends for Life
Description: Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
Study NCT01454362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Inhalation of nicotine.
Study NCT01454362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Inhalation of nicotine.
Study NCT00534755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breast Cancer database
Description: prospective breast cancer database
Study NCT04307979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High-fat coffee
Description: A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
Study NCT04307979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat coffee
Description: A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
Study NCT04307979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black coffee
Description: A regular black coffee with no added caloric content.
Study NCT00004228 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04307979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black coffee
Description: A regular black coffee with no added caloric content.
Study NCT04259281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102
Description: antisense oligonucleotide
Study NCT04340193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days
Study NCT05092932 — intervention group
Intervention type: OTHER
Intervention: Normal Foot Force
Description: LoadSol Insoles will be inserted into the participants shoes. The device measures the pressure distribution on the bottom of the foot. Participants will then be asked to walk normally, use crutches, use a walker, and use a wheeled knee scooter. The pressure placed throughout the foot will be analyzed and compared under different conditions. This testing will take approximately 10 minutes.
Study NCT04173845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianqi Pingchan Granule
Description: Tianqi Pingchan Granule are given twice a day
Study NCT04173845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tianqi Pingchan Granule Placebo
Description: Tianqi Pingchan Granule Placebo
Study NCT01313598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187
Description: continuous IV infusion
Study NCT04253821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index
Description: The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
Study NCT04623723 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )
Description: Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
Study NCT04623723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (FS-407, EMS® Piezon, Switzerland)
Description: Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
Study NCT00998816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
Study NCT00998816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
Study NCT04340193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on specified days
Study NCT04340193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE (Trans-arterial ChemoEmbolization)
Study NCT00908674 — intervention group
Intervention type: DRUG
Intervention: Cyproterone acetate (Androcur)
Description: The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months.
Study NCT02078830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Tegaderm™ CHG I.V. Securement Dressing
Description: Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
Study NCT02078830 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing
Description: Placebo Dressing with the same shape like the CHG-Dressing without CHG.
Study NCT01616719 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DTRAX Graft
Description: DTRAX Graft is an allograft implant inserted to support spinal fusion.
Study NCT04340193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE (Trans-arterial ChemoEmbolization)
Study NCT01515007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dispersion for inhalation
Study NCT01784380 — intervention group
Intervention type: DRUG
Intervention: Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin
Study NCT02782988 — intervention group
Intervention type: OTHER
Intervention: olfactory tests, otoacoustic emissions (OAE)
Description: Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
Study NCT01515007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01814618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Respules
Description: Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
Study NCT06091579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a Plastiape capsule-based dry powder inhaler.
Study NCT06091579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
Study NCT01893814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study NCT01893814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT02909114 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT
Study NCT01532219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Psychodynamic Treatment
Description: Ten weeks of guided self-help + therapist contact, via the Internet.
Study NCT01532219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered structured support
Description: Ten weeks of therapist contact, via the Internet.
Study NCT00715286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timing of surgery
Description: Surgery is followed by chemotherapy
Study NCT00715286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: timing of surgery
Description: Chemotherapy is followed by surgery